Replimune (REPL) Seeks FDA Approval After Leadership Change

AI Summary

Replimune (REPL) is making a third attempt to secure FDA approval for its therapies following the departure of CEO Philip Makary. The company aims to address previous regulatory concerns that have hindered its progress in bringing products to market. Leadership transitions often impact investor sentiment and operational strategy, making this attempt critical for Replimune's future. The outcome of this FDA review could significantly affect REPL's stock performance and market standing.